Medical technology company Teleflex (NYSE: TFX) will be reporting results tomorrow before market hours. Here’s what to expect.

Teleflex met analysts’ revenue expectations last quarter, reporting revenues of $892.9 million, up 16.8% year on year. It was a satisfactory quarter for the company, with a beat of analysts’ EPS estimates.

Is Teleflex a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.

This quarter, the market is expecting Teleflex’s revenue to grow 15.9% year on year, improving from the 2.8% increase it recorded in the same quarter last year.

Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Teleflex has missed Wall Street’s revenue estimates multiple times over the last two years.

Looking at Teleflex’s peers in the healthcare equipment and supplies segment, some have already reported their Q4 results, giving us a hint as to what we can expect. Intuitive Surgical delivered year-on-year revenue growth of 18.8%, beating analysts’ expectations by 1%, and Envista reported revenues up 15%, topping estimates by 10.6%. Intuitive Surgical’s stock price was unchanged after the resultswhile Envista was up 17.8%.

Read our full analysis of Intuitive Surgical’s results here and Envista’s results here.

Investors in the healthcare equipment and supplies segment have had fairly steady hands going into earnings, with share prices down 1.9% on average over the last month. Teleflex is up 7.3% during the same time and is heading into earnings with an average analyst price target of $129.25 (compared to the current share price of $112.12).

Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we’ve identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link.